Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Oct 21, 2016
Pharma Momentum Builds for Johnson & Johnson
Image Source: J&J. Dividend growth giant Johnson & Johnson reported impressive results in the third quarter of 2016 as momentum in its business continues to build. Oct 18, 2016
Are MLP Structures Phony?
Can an MLP stock value be created from nothing? Oct 14, 2016
Where I Went Wrong on Gilead
Image Source: torbakhopper. Let’s walk through our run-in with Gilead. Oct 1, 2016
Is OPEC For Real This Time?
OPEC has agreed to the outline of a deal to cut oil production in member nations for the first time in eight years, sending crude oil prices higher, but skepticism has surfaced over the cartel’s commitment to the capping of production. Aug 31, 2016
Nelson's Quick Thoughts on Midstream Energy MLPs
Image Source: Roy Luck. Let's get a quick update on Valuentum President of Investment Research Brian Nelson's thoughts on midstream energy MLPs. Jul 27, 2016
Gilead’s Harvoni Sales Dip Considerably in the US
Image Source: Gilead. The bull case for owning Gilead has become bleak. Jul 25, 2016
Dividend Increases/Decreases for the Week Ending July 22
Let's take a look at companies raising/lowering their dividends this week. Jul 1, 2016
Distributing Truth on MLPs
The near term outlook for many midstream MLPs has cleared up quite a bit, but our concerns with the long-term sustainability of the MLP business model remain. May 17, 2016
Big Pharma 1Q Earnings Roundup, Part II
Image Source: Paw Paw. Let’s take a look at the first quarter performance and some major news for some of the biggest players in the pharmaceuticals sector. Included in this article: ABBV, AGN, BMY, AMGN, MRK, PFE. May 3, 2016
A Letter from the President
“We’re Valuentum, not value – and that’s all the difference in the world.” – Brian Nelson, CFA The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
